Sermorelin Dosage Guide: Protocols, Timing & How Much to Take (2026)
From Peptidepedia, the trusted peptide wiki.
Medical Advisory Board
Dosage Protocols
Sermorelin dosing should be individualized by a licensed healthcare provider based on the patient's age, body weight, baseline IGF-1 levels, and treatment goals. The following ranges are derived from clinical literature and prescribing conventions at compounding pharmacies:
Standard anti-aging and wellness range: 200 to 300 mcg administered subcutaneously at bedtime, 5 to 7 nights per week
Conservative starting dose: 100 to 200 mcg at bedtime for the first 2 to 4 weeks, titrated upward based on tolerance and clinical response
Higher-end clinical dosing: 300 to 500 mcg at bedtime, typically reserved for patients with documented low IGF-1 levels or poor initial response
Pediatric dosing (historical FDA-approved): 30 mcg/kg subcutaneously at bedtime, as per the original Geref labeling
Most protocols employ 5-nights-per-week dosing (weekdays on, weekends off) to balance therapeutic benefit with physiological rest periods. Some providers prescribe nightly dosing for the first 3 to 6 months before transitioning to a 5-on/2-off schedule.
Frequently Asked Questions
Most anti-aging protocols use 200 to 300 mcg administered subcutaneously at bedtime, 5 nights per week. Dosing is individualized based on age, IGF-1 levels, and clinical response. A healthcare provider should determine the appropriate dose and monitor progress.
This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.
References
Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308.
Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96.
Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37.
Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159.
FDA. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register. 2013;78(42):14219-14220.
World Anti-Doping Agency. The 2025 Prohibited List International Standard.
Sermorelin Acetate. RxList Drug Database.
PubChem. Sermorelin (CID 16132413).
Sermorelin. DrugBank (DB00010).